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Introduction
Vascular endothelial growth factor (VEGF), a versatile proan-
giogenic growth factor was first described by Leung et al,1
althoughSenger et alfirst identified this protein 6 years earlier
but called it vascular permeability factor.2–4 The VEGF family
in humans consists of VEGF-A, placental growth factor(PLGF),
VEGF-B, VEGF-C, and VEGF-D. All are induced during hypoxic
stress in mammalian cells.5 VEGF-A is a homodimeric protein
and is believed to be a critical mediator of vasculogenesis
during embryogenesis. In humans, the gene encoding VEGF-A
is located on chromosome number 6 (6p12).5 VEGF is thought
to act on endothelial cells to bring about numerous effects,
including induction of angiogenesis, increased vascular per-
meability, and endothelial cell growth, through the promotion
of cell migration and inhibiting apoptosis. VEGF and notch
signaling engage in an intricate crosstalk to balance tip and
stalkcell formationandregulatedirected tipcellmigrationand
stalk cell proliferation.6
Vascular endothelial growth factor plays a central role in
both physiological and pathological angiogenesis and neo-
vascularization.7,8 The soluble forms of VEGF-A are the main
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Abstract Vascular endothelial growth factor-A (VEGF-A) plays an integral role in physiological
and pathophysiological angiogenesis and has increasingly been implicated in the
development of retinopathy of prematurity (ROP) in preterm infants. Application of
intravitreal anti-VEGF is frequently used to treat ROP with little consideration given to
the role of VEGF-A in neonatal growth and development. Previous studies have
demonstrated systemic anti-VEGF persistence, reduced peripheral VEGF levels follow-
ing treatment, and possible diagnostic and prognostic uses for VEGF-A determination.
This study seeks to determine a normal range for serum VEGF-A (sVEGF-A) in healthy,
term infants. The sVEGF-A levels were obtained from 32 neonates born at term infants
(16 males and 16 females) using an enzyme-linked immunosorbent assay. No
significant correlations were found between sVEGF-A levels and time of sample
collection, birth weight, or gender. The median sVEGF-A level was 976 (394–1635)
pg/mL (95% confidence interval for median: 496–1,318 pg/mL). This preliminary study
determines a normal range for the sVEGF-A level in healthy, term neonates. This normal
range will provide a tool to assist in the diagnosis, prognosis, and monitoring of
treatment of infants with ROP.
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isoforms that induce paracrine activation and proliferation
of endothelial cells through binding to the specific VEGF
tyrosine kinase receptors, VEGFR1 and VEGFR2 (predomi-
nantly).7 VEGF binding produces receptor activation and an
upregulation of receptor-related kinase activity, allowing for
phosphorylation of tyrosine residues and further upregula-
tion of cell signaling pathways, the mechanisms behind
which remain to be fully elucidated.7
Three VEGF tyrosine kinase receptors have been identi-
fied; FMS-like tyrosine kinase Flt-1 (VEGFR1/flt-1), VEGFR2/
KDR/Flk-1, and Flt-4/VEGFR3. VEGFR-1 has a high affinity for
VEGF-A and appears to modulate endothelial cell division at
the earliest stages of vascular development just before the
development of blood vessels. Through a complex series of
events, hypoxia upregulates both VEGF-A and VEGFR1 pro-
duction via hypoxia-inducible factor-1, a protein complex
which binds to enhancer sequences of the VEGF-A gene.
Various studies have also described the upregulation of
VEGFR2 following hypoxia.7
Retinopathy of prematurity (ROP), a retinal vasculoproli-
ferative disease that is exclusive to preterm neonates, has
become an important cause of preventable childhood blind-
ness worldwide.9,10 The established and traditional way to
treat this condition is by using laser photocoagulation to
ablate vast areas of peripheral retina thereby reducing
hypoxic drive and thus the retinopathy. However, over the
past 7 years, intravitreal VEGF inhibitor (anti-VEGF) therapy
has become an alternative treatment option for some clin-
icians.11 Intravitreally injected anti-VEGF has been subse-
quently detected in the systemic circulation in neonates.12,13
The level of serum VEGF-A (sVEGF-A) in term neonates
has not been well established. There has been a difference
noted between serum and plasma VEGF-A levels.14 Despite
the lack of this knowledge, clinicians are increasingly using
anti-VEGF to treat ROP. Hence, we performed a preliminary
study to determine the normal sVEGF-A level in term
neonates.
Materials and Methods
This prospective study was conducted in the Department of
Neonatology, Townsville Hospital, Queensland, Australia. The
Department of Neonatology is a tertiary perinatal center that
caters for a regionwithmore than 10,000 births each year. The
study commenced in July 2014, and the data presented in this
report are based on patients who were recruited until
July 2016. The patients recruited in this study are part of a
larger ongoing study that investigates the relationship among
prematurity, retinal vascularization, and renal development in
preterm and low birth weight neonates. The term, healthy
neonates (gestation>37weeks) who presented to the hospital
with minor neonatal conditions, such as neonatal jaundice,
feeding problems, and risk of infection, were eligible to be part
of this study. Neonates with congenital abnormalities or syn-
dromes and those needing respiratory support or surgerywere
excluded. Consent was obtained from the parents of all parti-
cipants included in the study. This study was approved by the
Townsville Health District Human Research Ethics Committee.
VEGF Measurement
Peripheral venous samples were obtained from neonates born
at term (completed 37 weeks’ gestation) for VEGF measure-
ment. Samples were transported and processed promptly
(within60minutes). VEGFmeasurementwasperformedusing
a VEGF human enzyme-linked immunosorbent assay (ELISA)
kit (ab100662, Abcam) which detects both VEGF-A165 and
VEGF-A121 isoforms with a sensitivity of 10 pg/mL and an
intra-assay precision (coefficient of variation [CV] %) of < 10%
and interassay precision (CV%) of < 12%.
Statistical analyses were performed using MedCalc Version
15.6 (MedCalc Software bvba, Mariakerke, Belgium). The nor-
mality of the variables was determined using the D’Agostino–
Pearson’s test.15Dataarepresentedasmean(standarddeviation
[SD]) or as median (interquartile range[IQR]). Student’s t-test
or Mann–Whitney’s test was used where appropriate, with
p-values < 0.05 considered significant.
Findings
Thirty-two term neonates were recruited, with a mean gesta-
tional age of 38.8 (1.2) weeks, and amean birthweight of 3,161
(648) g. The mean postnatal age for these infants at the time of
samplingwas 6.9 (4.3) days. Themedian sVEGF-A levelwas 976
(394–1,635) pg/mL (95% confidence interval [CI] for median:
496–1,318 pg/mL). Sixteen of the infants were females, and
there was no significant difference in sVEGF-A level between
femaleandmale infants (1,318 [498–2,046] vs. 793 [294–1,206]
pg/mL; p ¼ 0.073). There was no correlation between birth
weight and plasma VEGF-A levels (►Fig. 1). There was also no
significant correlation between time of sampling and VEGF-A
level (r ¼ 0.04, p ¼ 0.0832).
Discussion
There have been relatively few studies that have reported
sVEGF-A levels in infants and less reporting of sVEGF-A levels
in healthy term neonates. To our knowledge, this is the first
study to define the 95% CI for VEGF-A serum levels in healthy,
Fig. 1 No correlation between birth weight and VEGF-A level
(y ¼ 2,421.6681 þ x ¼  0.3959; p ¼ 0.135). VEGF-A, vascular
endothelial growth factor A.
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termneonates. Lassus et al16havepreviouslypublishedplasma
VEGF levels ina cohortof13 terminfants (138.5  39.4pg/mL).
Previously published human studies in premature neo-
nates have produced contradictory findings. A few have also
demonstrated increased concentrations of serum VEGF in
preterm neonates associated with certain conditions such
as ROP when compared with their normal counter-
parts.17–20 Yenice et al found serum VEGF levels taken
from cord blood at birth to be lower in neonates who later
developed ROP.21 VEGF antagonists are increasingly used as
a clinical treatment in neonates. The measurement of VEGF-
A levels in the blood has been extensively investigated as a
potential diagnostic biomarker. We believe the knowledge
of normal levels in healthy, term infants is essential to aid
clinical interpretation, prognostic, and diagnostic decision
making.
There are some limitations to our study. It is important to
note that VEGF-A measurement and interpretation can be
significantly affected by some preanalytical variables, such
as the sample type, serum versus plasma, and the method of
analysis multiplexed immunoassay versus ELISA.22 In this
study, serum samples were analyzed using a standard ELISA
assay. The95%CI formedian 496 to1,318pg/mL is comparable
to that reported byother studies.12,13,21,23–25 This CI for serum
VEGF-A is higher than that reported by Lassus et al from their
analysis of plasma VEGF.16 Serum samples may have a higher
concentrationofVEGF-Apossiblydue to the releaseofplatelet-
derived VEGF-A.14 It is also unclear if systemic VEGF-A mea-
surement accurately reflects thebiological effect of VEGF-A, as
VEGF signaling is increasingly recognized for its function
outside of the vascular system, notably during neural devel-
opment, and blood vessels regulate epithelial branching mor-
phogenesis.26Another limitation of our study is the variability
in the infants’ postnatal age. However, this study did not find
anysignificantcorrelationbetweenageat the timeof sampling
and VEGF-A level. Some of the infants in our cohort required
phototherapy for jaundice, and there are data to suggest that
phototherapy may influence serum VEGF levels.27
Conclusion
This study reports a 95% CI for serumVEGF-A levels on healthy
term infants. The sVEGF-A levels were independent of age at
the time of sample collection, birth weight, and gender. This
normal reference range may serve as a tool for assisting the
diagnosis, prognosis, and effects of anti-VEGF treatment. How-
ever, it has to be appreciated that there may be a difference
betweenserumandplasma levelsofVEGF-AandthatVEGF-A is
being recognized for its functionoutsideof thevascular system.
Note
Consent was obtained from parents of all participants in-
cluded in the study. This study was approved by the Towns-
ville Health District Human Research Ethics Committee.
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